Key facts
- RhythmScience’s last known valuation is $30.0M (Mar 2023).
- It has raised $7.6M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Matter (Consulting Services (B2B)), TenOneTen Ventures, Cedars Sinai Health Ventures, OCA Ventures, Press On Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for RhythmScience
- ·The full record, as it builds
Funding rounds
No funding rounds for RhythmScience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About RhythmScience
Developer of a healthcare management platform designed to organize and simplify cardiac data management for clinicians. The company's platform offers a unified workspace that integrates data from various cardiac devices and allows healthcare organizations to document their work, manage volumes of data and stay in touch with patients at all hours of the day, enabling doctors to manage hypertension, heart failure, and rhythm disorders more efficiently, improving patient outcomes and care coordination.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 18
- Website
- rhythm360.io/
- Ownership
- Privately Held (backing)
RhythmScience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in RhythmScience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on RhythmScience in its N-PORT filings yet. We sweep new filings monthly.